Patients treated with Flt3L displayed a potent expansion of DCs, which could be purified, loaded with tumor antigens and reinfused.27 Although final reports for several clinical trials using Flt3L are still expected, the use of Flt3L as a coadjuvant in tumor vaccination reported promising results at improving priming of antitumor cytotoxic T cell responses.28 Our results suggest that DNGR-1 blockade holds therapeutic potential in this context. The gene discussed is CLEC9A; the disease is neoplasm.